Survodutide (BI 456906) is a synthetic dual agonist of the glucagon and GLP-1 receptors, developed by Boehringer Ingelheim and Zealand Pharma. Like mazdutide, it derives its dual mechanism from the natural gut hormone oxyntomodulin, but with engineered structural changes to extend the half-life and balance receptor pharmacology for clinical use. Survodutide is in Phase 3 development across obesity, type 2 diabetes and MASH (metabolic dysfunction-associated steatohepatitis), with notable Phase 2 readouts showing strong activity in MASH — where the glucagon-receptor arm appears particularly active on hepatic steatosis biology.
Survodutide acts as a co-agonist at the GLP-1 receptor and the glucagon receptor — the same dual mechanism as mazdutide and oxyntomodulin itself, though with different engineering choices in the molecular structure. The GLP-1 arm provides the now-characterised satiety, gastric-emptying and glucose-control effects of the incretin class; the glucagon arm drives hepatic lipid mobilisation, glycogenolysis and increased resting energy expenditure.
The MASH research finding deserves separate attention. Glucagon receptor activation in the liver drives hepatic fatty-acid oxidation and lipolysis — both directly relevant to the pathophysiology of MASH, in which hepatocytes accumulate triglyceride and undergo inflammation. The glucagon arm of dual agonists appears to confer hepatic-fat reduction effects beyond what GLP-1 monotherapy achieves at equivalent weight loss — a pharmacologic distinction with clear translational implications for the MASH indication.
Survodutide's Phase 2 MASH readouts have been among the most clinically meaningful in the field, with high rates of MASH resolution and fibrosis improvement reported in published trial data — positioning the compound as a leading MASH research candidate.
Survodutide's Phase 2 MASH programme reported substantial rates of MASH resolution without fibrosis worsening, alongside meaningful fibrosis improvement in the higher-dose cohorts. The trial readouts were notable for the magnitude of hepatic-fat reduction (>50% in the higher-dose arms) and the proportion of subjects achieving the histologic primary endpoints.
The result has positioned survodutide as a leading MASH research candidate. The compound holds FDA Breakthrough Therapy designation for MASH, reflecting the unmet clinical need and the strength of the Phase 2 data. Phase 3 MASH trials are ongoing.
Survodutide's obesity Phase 2 (SURPASS-equivalent design) documented mean weight reductions of approximately 19% at the higher-dose cohorts over 46 weeks — comparable to tirzepatide and substantially above semaglutide monotherapy at the same protocol length. The compound is in Phase 3 obesity development.
The parallel T2D programme has reported HbA1c reductions consistent with other long-acting incretins in the class, with the dual-mechanism producing additional weight loss compared with selective GLP-1 monotherapy.